Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Flora Growth Corp. (FLGC) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic
$0.74
-0.03 (-4.38%)Did FLGC Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Flora Growth is one of their latest high-conviction picks.
Based on our analysis of 7 Wall Street analysts, FLGC has a bullish consensus with a median price target of $2.75 (ranging from $1.50 to $4.00). Currently trading at $0.74, the median forecast implies a 270.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Rommel Dionisio at Aegis Capital, projecting a 439.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for FLGC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 25, 2024 | Aegis Capital | Rommel Dionisio | Buy | Initiates | $4.00 |
Aug 15, 2024 | Alliance Global Partners | Aaron Grey | Neutral | Downgrade | $0.00 |
May 16, 2024 | Roth MKM | Bill Kirk | Buy | Reiterates | $6.00 |
Apr 3, 2024 | Roth MKM | William Kirk | Buy | Maintains | $7.00 |
Jun 1, 2023 | Roth MKM | Buy | Maintains | $0.00 | |
May 18, 2023 | Roth MKM | Bill Kirk | Buy | Maintains | $1.00 |
Apr 19, 2023 | Roth MKM | Buy | Maintains | $0.00 | |
Feb 1, 2023 | Argus Research | Steve Silver | Buy | Maintains | $3.00 |
Oct 25, 2022 | Alliance Global Partners | Aaron Grey | Buy | Maintains | $2.00 |
Sep 23, 2022 | Alliance Global Partners | Aaron Grey | Buy | Initiates | $2.50 |
Aug 1, 2022 | Cantor Fitzgerald | Pablo Zuanic | Neutral | Initiates | $0.85 |
Oct 13, 2021 | Roth Capital | Buy | Initiates | $0.00 | |
Jun 23, 2021 | MKM Partners | Buy | Initiates | $0.00 |
The following stocks are similar to Flora Growth based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Flora Growth Corp. has a market capitalization of $17.51M with a P/E ratio of -0.6x. The company generates $53.26M in trailing twelve-month revenue with a -25.0% profit margin.
Revenue growth is -34.6% quarter-over-quarter, while maintaining an operating margin of -17.8% and return on equity of -336.7%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Cultivates and distributes cannabis products sustainably.
The company generates revenue through the cultivation and distribution of cannabis products across pharmaceuticals, cosmetics, and consumer packaged goods sectors. By optimizing its supply chain for cost-effectiveness and leveraging its operations in Colombia, Flora Growth Corp. can meet diverse consumer needs in both medical and recreational markets.
Flora Growth Corp. is positioned in the rapidly evolving global cannabis industry, focusing on sustainable practices and enhancing the accessibility of cannabis-derived products. Its commitment to organic cultivation and adherence to health and wellness trends are key aspects of its operational strategy.
Healthcare
Drug Manufacturers - Specialty & Generic
64
Mr. Clifford A. Starke
United States
2021
Flora Growth Corp. (NASDAQ: FLGC) reported its financial results for 2024, highlighting potential for cannabis reform in the U.S. following the re-election of President Trump.
Flora Growth Corp.'s results and Trump's re-election signal potential cannabis reform, which could enhance market conditions and growth opportunities for cannabis companies.
Flora Growth Corp. appointed Patrick Moloney as Head of Product Development for its Vessel brand, leveraging his 20+ years of experience in product innovation.
Patrick Moloney's appointment as Head of Product Development could enhance Flora Growth Corp.'s product innovation, potentially driving revenue and increasing market competitiveness.
Flora Growth Corp. (NASDAQ: FLGC) closed a registered direct offering, selling 2.85 million shares at $1.25 each, raising approximately $3.6 million from institutional investors.
Flora Growth Corp.'s $3.6 million share offering may dilute existing shares, impacting stock value. Institutional interest indicates confidence but raises concerns about future earnings.
Flora Growth Corp. granted 900,000 Restricted Stock Awards to Clifford Starke, fully vesting on December 15, 2024. Starke holds 1,346,902 Common Shares (7.80% total).
Flora Growth Corp.'s issuance of 900,000 Restricted Stock Awards to Clifford Starke signals increased insider confidence, potentially influencing stock performance and investor sentiment.
Flora Growth Corp. (NASDAQ: FLGC) announced a registered direct offering of 2,850,000 Common Shares at $1.25 each, totaling approximately $3.6 million, with institutional investors.
Flora Growth Corp.'s $3.6 million share offering at $1.25 per share indicates capital raising efforts, impacting liquidity and potentially diluting existing shares, affecting stock value.
Flora Growth Corp. (NASDAQ: FLGC) plans to apply for cannabis pilot programs in Germany aimed at reducing the illicit market and enhancing health prevention, as announced on December 12, 2024.
Flora Growth's application for German cannabis pilot programs could enhance its market position, drive revenue growth, and reduce competition from the illicit market, appealing to investors focused on legal cannabis expansion.
Based on our analysis of 7 Wall Street analysts, Flora Growth Corp. (FLGC) has a median price target of $2.75. The highest price target is $4.00 and the lowest is $1.50.
According to current analyst ratings, FLGC has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.74. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict FLGC stock could reach $2.75 in the next 12 months. This represents a 270.6% increase from the current price of $0.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company generates revenue through the cultivation and distribution of cannabis products across pharmaceuticals, cosmetics, and consumer packaged goods sectors. By optimizing its supply chain for cost-effectiveness and leveraging its operations in Colombia, Flora Growth Corp. can meet diverse consumer needs in both medical and recreational markets.
The highest price target for FLGC is $4.00 from Rommel Dionisio at Aegis Capital, which represents a 439.1% increase from the current price of $0.74.
The lowest price target for FLGC is $1.50 from at , which represents a 102.2% increase from the current price of $0.74.
The overall analyst consensus for FLGC is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.75.
Stock price projections, including those for Flora Growth Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.